Plain-English translation of NCT06127290 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is following HIV patients in Russia and Eastern Europe who are starting treatment with a newer class of HIV medication called INSTI (integrase strand transfer inhibitors). Researchers want to understand how the virus evolves, whether it develops resistance to medications, and how well these newer drugs work in this region over time.
HIV can develop resistance to medications, making treatment less effective. This study aims to track these changes as newer treatments are introduced in Eastern Europe and Russia, so doctors can better understand what's working and prepare for new treatment options.
You likely qualify if…
You likely don't qualify if…
You would continue your regular HIV treatment while the research team monitors your progress and collects your viral samples and clinical data. The study involves both short-term and long-term follow-up visits where researchers will track how your virus responds to the medication and whether any resistance develops. You'll need to provide consent for your medical information and samples to be part of a shared research database.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Germany
Italy
Poland
Sweden
Sponsor
Euresist Network GEIE
Collaborators
Karolinska Institutet, University of Siena
Enrollment target
~200 participants
Started
December 2021
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
FRANCESCA INCARDONA
Euresist Network GEIE
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.